SCHEMBL6629282

SCHEMBL6629282

Cc1cc(C)cc(COc2ccc(OC(=O)CN)cc2)c1

nearest known ligand 0.64

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PARP10 Q53GL7 3/20 0.64
HDAC8 Q9BY41 2/20 0.51
MAOB P27338 4/20 0.50
CYP3A4 P08684 1/20 0.46
ALDH1A1 P00352 1/20 0.44
MAPT P10636 1/20 0.44
MAPK1 P28482 1/20 0.44
LTA4H P09960 1/20 0.44
LMNA P02545 1/20 0.44
GAA P10253 1/20 0.44
TSPO P30536 1/20 0.43
PTPRC P08575 1/20 0.43
PTPRF P10586 1/20 0.43
PTPN1 P18031 1/20 0.43
NR1H4 Q96RI1 1/20 0.43
NPC1 O15118 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5843729 0.80 LTA4H (0.63) PARP10MAOBMAPTLTA4HLMNA
SCHEMBL2592352 0.78 LMNA (0.57) ALDH1A1MAPTLMNAGAANPC1
SCHEMBL5370546 0.77 PARP10 (0.65) PARP10HDAC8MAOBALDH1A1MAPT
SCHEMBL13886605 0.74 MAOB (0.60) PARP10MAOB
SCHEMBL28567068 0.74 PARP10 (0.62) PARP10HDAC8MAOBALDH1A1MAPT
SCHEMBL23566127 0.74 MAOB (0.61) PARP10MAOB
SCHEMBL11484095 0.74 PARP10 (0.54) PARP10HDAC8MAOBCYP3A4MAPT
SCHEMBL6629474 0.74 HDAC8 (0.62) PARP10HDAC8MAOBALDH1A1MAPT
SCHEMBL561023 0.73 KMT2A (0.45) PARP10CYP3A4ALDH1A1MAPTLMNA
SCHEMBL11151702 0.73 KMT2A (0.45) PARP10CYP3A4ALDH1A1MAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1027332-B1 NOVEL LACTAM METALLOPROTEASE INHIBITORS BRISTOL MYERS SQUIBB PHARMA CO (US) 2004-05-26 EP disclosed
US-6610731-B2 Antiinflammatory BRISTOL-MYERS SQUIBB COMPANY 2003-08-26 US disclosed
US-20030134827-A1 Novel lactam metalloprotease inhibitors DUAN JINGWU (US) 2003-07-17 US disclosed
US-6403632-B1 CYCLIC AMIDE DERIVATIVE BRISTOL MYERS SQUIBB PHARMA CO (US) 2002-06-11 US disclosed
EP-1027332-A1 NOVEL LACTAM METALLOPROTEASE INHIBITORS Du Pont Pharmaceuticals Company (US) 2000-08-16 EP disclosed
US-6057336-A ANTIINFLAMMATORY AGENTS E. I. DU PONT DE NEMOURS AND COMPANY (US) 2000-05-02 US disclosed
WO-1999018074-A1 NOVEL LACTAM METALLOPROTEASE INHIBITORS Britol-Myers Squibb Pharma Company (US) 1999-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030134827-A1 Novel lactam metalloprotease inhibitors ADAM9, ADAM8, ADAM17 PARP10 2014/4885HDAC8 270/4885MAOB 402/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.